Novartis AG
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NVSEF research report →
Companywww.novartis.com
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers.
- CEO
- Vasant Narasimhan
- IPO
- 2010
- Employees
- 75,883
- HQ
- Basel, CH
Price Chart
Valuation
- Market Cap
- $272.19B
- P/E
- 21.34
- P/S
- 5.19
- P/B
- 7.45
- EV/EBITDA
- 15.00
- Div Yield
- 3.12%
Profitability
- Gross Margin
- 75.13%
- Op Margin
- 29.88%
- Net Margin
- 24.31%
- ROE
- 31.54%
- ROIC
- 14.89%
Growth & Income
- Revenue
- $57.13B · 10.45%
- Net Income
- $14.65B · 22.68%
- EPS
- $7.56 · 27.70%
- Op Income
- $17.80B
- FCF YoY
- 33.53%
Performance & Tape
- 52W High
- $171.29
- 52W Low
- $109.80
- 50D MA
- $149.24
- 200D MA
- $138.21
- Beta
- 0.49
- Avg Volume
- 50.76K
Get TickerSpark's AI analysis on NVSEF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our NVSEF Coverage
We haven't published any research on NVSEF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NVSEF Report →